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639Abstracts
only 50% of the average salary the costs outweigh the beneﬁt.
CONCLUSIONS: The beneﬁt to an employer depends on the
organization of the company and the value of reducing illness
related work absence. These results indicate that providing
inﬂuenza treatment may be a cost-saving intervention for
employers. In addition, employees will beneﬁt from improved
quality of life.
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OBJECTIVES: In immunocompromised patients, presumed 
systemic fungal infections (SFI) are treated empirically with an
intravenous (IV) antifungal to reduce the occurrence of docu-
mented infections and associated mortality. Amphotericin B (AB)
remains the treatment of choice. The toxicity of conventional AB
(CAB) often results in discontinuation or suboptimal dosing.
Liposomal or lipid formulations of AB (LAB), with improved
toxicity proﬁle, are extremely expensive. The objective was to
compare the cost-effectiveness of intravenous itraconazole
(IVitra) with CAB and LAB as empirical treatment of presumed
SFI in neutropenic cancer and bone marrow transplant (BMT)
patients. METHODS: A medical decision tree was developed,
including probabilities of toxicity, response, pathogen documen-
tation and 2nd line treatments. Clinical data were obtained from
randomized trials comparing IVitra with CAB (n = 392) and CAB
with LAB (n = 687). Resource use was obtained via modiﬁed
Delphi consensus panel, unit costs from ofﬁcial sources (public
payer perspective). Cost-effectiveness was expressed as cost 
per additional “responder” (deﬁned as patient without fever or
major toxicity). RESULTS: The total cost per neutropenic cancer
patient was lowest for IVitra (7486€), followed by CAB (9721€)
and LAB (11,956€). The same cost ranking was obtained in BMT
patients, however with higher hospitalization costs. The vari-
ables accounting for cost differences between strategies were 1st
and 2nd line antifungal drug costs. In cost-effectiveness analysis,
IVitra was dominant over CAB combining greater “effective-
ness” (because of less toxicity) and lower costs. The incremen-
tal cost-effectiveness ratios for LAB over IVitra in neutropenic
cancer and BMT patients were 188,638€/“responder” and
206,865€/“responder” respectively. CONCLUSIONS: IVitra
was shown to be a cost-effective empirical treatment for pre-
sumed SFI in neutropenic cancer and BMT patients and to be
cost saving compared to both CAB and LAB. These conclusions
are similar to those for UK, Germany, Italy and Sweden, in which
the same analysis was performed earlier.
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OBJECTIVES: Most decision-analyses for chronic hepatitis C
(CHC) treatment ignore co-morbid illness associated with CHC,
leading to overly optimistic results. Therefore, we sought: 1) to
predict population-based clinical and economic burden of CHC
and associated diseases for the next 20 years in Germany, and
2) to examine the potential impact of different antiviral treat-
ment (AVT) policies. METHODS: The German Hepatitis C
Model (GEHMO), a validated and published CHC Markov
model, was linked to German CHC prevalence and incidence
data to project the morbidity, mortality and costs for all treat-
able patients with known CHC and elevated transaminases in
Germany. The model considered HCV genotype and CHC-asso-
ciated diseases (e.g., HIV co-infection, hemophilia, extra-hepatic
manifestations) and evaluated the following policies: 1) no AVT,
2) interferon monotherapy, and 3) interferon plus ribavirin, and
(4) pegylated interferon plus ribavirin. For each policy, the model
calculated the incidence of clinical complications, CHC-related
deaths, population life years (LY), quality-adjusted life years
(QALY), costs, and incremental cost-effectiveness ratios (ICER).
We used treatment efﬁcacy data from meta-analyses of random-
ized clinical trials and literature-based epidemiologic data on co-
morbidities. We adopted a societal perspective with a 3% annual
discount rate. RESULTS: In the absence of AVT during the next
20 years, HCV would cause more than 16,000 CHC-related
deaths and 29,000 cases of liver cirrhosis leading to 1200 liver
transplantations. Peginterferon plus ribavirin would prevent
about half of these complications and would add about 53,000
LY (or 49,000 QALYs) at a total cost of 1.3€ billion (undis-
counted values). In the discounted lifetime analysis, peginter-
feron plus ribavirin was the most effective strategy with an ICER
of 23,000€/QALY compared with interferon monotherapy (next
non-dominated strategy). CONCLUSIONS: Incorporating co-
morbid illnesses associated with CHC increased the ICER 
of peginterferon plus ribavirin, but treatment remained cost-
effective and would halve the burden of disease.
METHODS & CONCEPTS I
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OBJECTIVE: To evaluate three measures of compliance by
applying established methodologies for each to one population.
METHODS: Prescription claims data for 1164 patients receiv-
ing a chronic lipid-lowering medication (a combination product
versus a statin) in 2002–2003 were obtained; MPRs, PDCs, and
ELPTs were calculated. Because each method has different inclu-
sion criteria, the measures were analyzed for three different
subsets of the overall population. A second set of analyses was
conducted on a fourth subset of patients (those included in all
three of the other analyses) to evaluate the impact of inclusion
criteria on the endpoints. Logistic regression analyses were con-
ducted for each measure to determine the probability of being
categorized as “compliant” by established deﬁnitions. RESULTS:
The results differed depending on the methodology used, sug-
gesting each measure evaluates a different aspect of overall com-
pliance. MPR analysis demonstrated higher overall compliance
rates with the combination product versus statins (p = 0.001).
PDC analysis demonstrated lower compliance rates with the
combination product versus statins (2nd quarter p = 0.003, 4th
quarter p = 0.011). ELPT analysis also demonstrated lower com-
pliance rates for the combination product versus statins (6th
